Research Analysts’ Weekly Ratings Changes for Protagonist Therapeutics (PTGX)

A number of firms have modified their ratings and price targets on shares of Protagonist Therapeutics (NASDAQ: PTGX) recently:

• 11/19/2024 – Protagonist Therapeutics had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $58.00 price target on the stock.
• 11/19/2024 – Protagonist Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $50.00 price target on the stock.
• 11/11/2024 – Protagonist Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $50.00 price target on the stock.
• 11/4/2024 – Protagonist Therapeutics had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $58.00 price target on the stock.
• 9/25/2024 – Protagonist Therapeutics was upgraded by analysts at TD Cowen to a “strong-buy” rating.
• 9/24/2024 – Protagonist Therapeutics is now covered by analysts at TD Cowen. They set a “buy” rating and a $65.00 price target on the stock.

Protagonist Therapeutics Trading Up 5.2 %

NASDAQ PTGX opened at $40.65 on Thursday. Protagonist Therapeutics, Inc. has a 1-year low of $16.80 and a 1-year high of $48.89. The stock’s 50 day moving average is $45.43 and its two-hundred day moving average is $38.99. The company has a market capitalization of $2.42 billion, a price-to-earnings ratio of 15.28 and a beta of 2.17.

Insider Buying and Selling at Protagonist Therapeutics

In other news, insider Arturo Md Molina sold 1,906 shares of the stock in a transaction on Friday, November 15th. The stock was sold at an average price of $40.98, for a total transaction of $78,107.88. Following the sale, the insider now owns 46,444 shares in the company, valued at approximately $1,903,275.12. This represents a 3.94 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director William D. Waddill sold 8,000 shares of the firm’s stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $45.00, for a total transaction of $360,000.00. Following the completion of the sale, the director now owns 12,000 shares of the company’s stock, valued at $540,000. The trade was a 40.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 24,109 shares of company stock worth $1,069,999 over the last three months. Company insiders own 5.40% of the company’s stock.

Institutional Trading of Protagonist Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in PTGX. Sei Investments Co. lifted its stake in shares of Protagonist Therapeutics by 12.2% in the 1st quarter. Sei Investments Co. now owns 41,758 shares of the company’s stock valued at $1,208,000 after purchasing an additional 4,529 shares during the period. Russell Investments Group Ltd. acquired a new position in Protagonist Therapeutics in the first quarter valued at about $35,000. ProShare Advisors LLC boosted its holdings in Protagonist Therapeutics by 9.2% during the first quarter. ProShare Advisors LLC now owns 14,345 shares of the company’s stock worth $415,000 after buying an additional 1,206 shares during the last quarter. Vanguard Group Inc. grew its position in shares of Protagonist Therapeutics by 1.2% during the 1st quarter. Vanguard Group Inc. now owns 3,192,971 shares of the company’s stock worth $92,373,000 after buying an additional 39,055 shares during the period. Finally, Seven Eight Capital LP acquired a new position in shares of Protagonist Therapeutics during the 1st quarter worth about $202,000. 98.63% of the stock is owned by institutional investors.

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.